SFOSF Stock Chart & Stats
$2.20
$0.18(8.91%)
At close: 4:00 PM EDT
$2.20
$0.18(8.91%)
Day’s Range― - ―
52-Week Range$2.02 - $3.50
Previous CloseN/A
Volume620.00
Average Volume (3M)46.00
Market Cap
$8.36B
Enterprise Value$84.21K
Total Cash (Recent Filing)$15.29B
Total Debt (Recent Filing)$31.86B
Price to Earnings (P/E)17.1
Beta-0.03
Next Earnings
Aug 26, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield2.61%
Share Statistics
EPS (TTM)1.61
Shares Outstanding551,940,500
10 Day Avg. Volume20
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.21Price Target Upside45.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.19
Revenue Forecast (FY)$5.54B
Bulls Say, Bears Say
Bulls Say
Diversified Multi-segment ModelFosun Pharma’s exposure to manufacturing, distribution and healthcare services creates multiple durable revenue streams. This diversification lowers reliance on any single product or channel, supports cross-selling into hospital networks, and stabilizes earnings across product cycles over months to years.
Sharp TTM Revenue Rebound And Healthy MarginsA large TTM revenue rebound with sustained gross margins indicates recovering demand and preserved pricing/production economics. Over a 2–6 month horizon this supports reinvestment in commercialization and R&D, and suggests product mix improvements driving durable top-line and margin recovery.
Operating Cash Flow And FCF Turned PositiveSustained operating cash generation and a return to positive free cash flow signal improving cash discipline after prior deficits. Positive FCF provides internal funding for capex, product launches and working capital needs, reducing near-term dependence on external financing.
Bears Say
Weak Cash ConversionFCF equal to roughly a quarter of net income and a volatile cash history indicate earnings quality risks. Over several months this weak conversion makes the business vulnerable to working-capital swings, constrains discretionary spend, and increases refinancing or liquidity risk if investments rise.
Moderate LeverageA debt-to-equity around 0.75 represents meaningful leverage that reduces financial flexibility. In a 2–6 month window, leverage raises interest and covenant sensitivity, limits scope for large M&A or aggressive investment, and increases downside risk if revenue or cash flow softness recurs.
Only Average Returns; Margin PressurePersistent mid-single-digit ROE and falling EBITDA margin suggest structural cost or mix headwinds limiting long-term profitability. Over months this constrains capital allocation returns and shareholder value creation, and signals limited pricing power versus peers in core segments.
Shanghai Fosun Pharmaceutical (Group) Co News
SFOSF FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was $2.02 and its highest was $3.50 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is $8.36B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Aug 26, 2026 which is in 26 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported $0.049 earnings per share for the quarter, beating the consensus estimate of $0.048 by <$0.001.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of $0.057 which represents an annual dividend yield of 2.61%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.05.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of $0.049 in its last earnings report, beating expectations of $0.048. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in SFOSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
2.61%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
SFOSF Stock 12 Month Forecast
Average Price Target
$3.21
▲(45.75% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―
Ownership Overview
―
Insiders
3.58% Mutual Funds
― Other Institutional Investors
94.03% Public Companies and
Individual Investors